Medical Advisory Committee Sample Clauses

Medical Advisory Committee. In the event the Cap Medical Plan is to be modified pursuant to Section 23.2.4 – Medical Schedule of Benefits, the County shall convene the Medical Advisory Committee. The Association shall be given advance notice of such meeting and the union representative and one (1) bargaining unit member, designated by the union, shall be afforded the opportunity to attend and participate in the Medical Advisory Committee meeting. The Medical Advisory Committee shall not replace the parties’ RCW 41.56 obligations. The County intends (but does not guarantee data availability) to review medical utilization cost and medical benefits beginning in July of each year in preparation for Cap plan choices for the following year.
Sample 1Sample 2
AutoNDA by SimpleDocs
Medical Advisory Committee. Each member will be entitled to participate in the election of the Medical Advisory Committee and receive one vote per person regardless of the number of membership units owned. This Committee will be elected six (6) months after the commencement of LR Procedures at the Center. Until said Committee is elected, the Board of Directors will serve in that capacity. Further, the members, as a group, will be entitled to elect one member to the Board of Directors of TrueVision of Albuquerque, Inc.
Sample 1
Medical Advisory Committee. The Company shall establish a Medical Advisory Committee. A Chairman of the Medical Advisory Committee shall be appointed by the holders of a majority of the Membership Interests held by Physician Investors and Physician Entities and, as Chairman, he shall determine the number of members of the Center surgical staff to be appointed to the Medical Advisory Committee. The Chairman shall be a Physician Investor or an Owner, and the Chairman shall not be the same person as the Physician Director unless agreed to by approved by the holders of not less than sixty percent (60%) of the Membership Interests held by Physician Investors and Physician Entities. The Chairman shall serve until such time as he shall be replaced by the Board of Directors. Replacements to the Medical Advisory Committee shall be made in the sole discretion of the Chairman. The Medical Advisory Committee will act as the “Executive Committee” of the Medical Staff of the Center, as the same may be specified from time to time in the Center’s Medical Staff Bylaws. The Medical Advisory Committee will be responsible for developing utilization, peer review and quality assurance standards for the Center, reviewing utilization of Center services and generally making recommendations to the Board of Directors regarding the services provided at the Center. The Medical Advisory Committee, acting upon advice and counsel of counsel to the Company, may also adopt and implement additional requirements upon Members and their Affiliates, including without limitation the Owners, in order to enable the Company to comply or to attempt compliance with any healthcare regulatory schemes applicable to the Company, the Center, the Members, or the Owners.
Sample 1
Medical Advisory Committee. The LLC shall establish a Medical Advisory Committee comprised of six (6) Individual Investors who are physicians appointed by the Managers and one (1) physician appointed by the Hospital. The Medical Advisory Committee will be responsible for developing utilization, peer review and quality assurance standards for the Surgery Center, reviewing utilization of Surgery Center services and generally making recommendations to the Managers regarding the services provided at the Surgery Center.
Sample 1
Medical Advisory Committee. 5. In recognition of the impact to four full-time employees currently covering employee, spouse, and child(ren), the County agrees for 2021 only to keep them whole by contributing one hundred percent (100%) of the premium cost to maintain full family coverage. The four employees are:  Xxxxxxxx Xxxxxxx  Xxxxxx Xxxxxx  Xxxxxxxxx Xxxxxxx  Xxxxxx Xxxxx
Sample 1

Related to Medical Advisory Committee

  • Advisory Committee The Settling State shall designate an Opioid Settlement Remediation Advisory Committee (the “Advisory Committee”) to provide input and recommendations regarding remediation spending from that Settling State’s Abatement Accounts Fund. A Settling State may elect to use an existing advisory committee or similar entity (created outside of a State-Subdivision Agreement or Allocation Statute); provided, however, the Advisory Committee or similar entity shall meet the following requirements:

  • Development Committee As soon as practicable, the Parties will establish a joint development committee, comprised of at least one (1) and up to two (2) representatives of Omega and at least one (1) and up to two (2) representatives of Acuitas (the “JDC”). One such representative from each Party will be such Party’s Workplan Leader. Each Party may replace its Workplan Leader and other JDC representatives at any time upon written notice to the other Party, provided, however, that each Party shall use reasonable efforts to ensure continuity on the JDC. With the consent of the other Party (which will not be unreasonably withheld, conditioned or delayed), each Party may invite non-voting employees and consultants to attend JDC meetings as necessary, subject to consultant’s agreement to be bound to the same extent as a permitted subcontractor under Section 3.1(i).

  • Transition Committee 8.1.0 A transition committee comprised of the employee representatives and the employer representatives, including the Crown, will be established by January 31, 2016 to address all matters that may arise in the creation of the Trust.

  • Management Committee The Members shall act collectively through meetings as a "committee of the whole," which is hereby named the "Management Committee." The Management Committee shall conduct its affairs in accordance with the following provisions and the other provisions of this Agreement:

  • Steering Committee The Project Manager shall set up a Steering Committee for the Project, consisting of representatives from the Department, the Contractor, and any other key organisations whom the project will impact on, to be agreed between the parties. The function of the Steering Committee shall be to review the scope and direction of the Project against its aims and objectives, monitor progress and efficiency, and assess, manage and review expected impact and use of the findings from the Project. The Committee shall meet at times and dates agreed by the parties, or in the absence of agreement, specified by the Department. The Contractor’s representatives on the Steering Committee shall report their views on the progress of the Project to the Steering Committee in writing if requested by the Department. The Contractor’s representatives on the Steering Committee shall attend all meetings of the Steering Committee unless otherwise agreed by the Department.

  • Joint Development Committee The Parties shall form a joint development committee (the “Joint Development Committee” or “JDC”), made up of an equal number of representatives of Merck and BioLineRx, which shall have responsibility of coordinating all regulatory and other activities under, and pursuant to, this Agreement. Each Party shall designate a project manager (the “Project Manager”) who shall be responsible for implementing and coordinating activities, and facilitating the exchange of information between the Parties, with respect to the Study. Other JDC members will be agreed by both Parties. The JDC shall meet as soon as practicable after the Effective Date and then no less than twice yearly, and more often as reasonably considered necessary at the request of either Party, to provide an update on the progress of the Study. The JDC may meet in person or by means of teleconference, Internet conference, videoconference or other similar communications equipment. Prior to any such meeting, the BioLineRx Project Manager shall provide an update in writing to the Merck Project Manager, which update shall contain information about the overall progress of the Study, recruitment status, interim analysis (if results available), final analysis and other information relevant to the conduct of the Study. In addition to a Project Manager, each Party shall designate an alliance manager (the “Alliance Manager”), who shall endeavor to ensure clear and responsive communication between the Parties and the effective exchange of information, and shall serve as the primary point of contact for any issues arising under this Agreement. The Alliance Managers shall have the right to attend all JDC meetings and may bring to the attention of the JDC any matters or issues either of them reasonably believes should be discussed, and shall have such other responsibilities as the Parties may mutually agree in writing. In the event that an issue arises and the Alliance Managers cannot or do not, after good faith efforts, reach agreement on such issue, the issue shall be elevated to the Head of Clinical Oncology for Merck and the Vice President of Medical Affairs or Business Development for BioLineRx.

  • Special Committee The term “Special Committee” shall have the meaning as provided in Section 13(a).

  • Research Committee 2.2.1 Establishment and Functions of RC. ---------------------------------

  • Operating Committee the Consortium’s managing body, composed of representatives of the Manager and the Contractors, pursuant to Annex XI.

  • Advisory Board (a) The Managing Member may establish an Advisory Board comprised of members of the Managing Member’s expert network and external advisors. The Advisory Board will be available to provide guidance to the Managing Member on the strategy and progress of the Company. Additionally, the Advisory Board may: (i) be consulted with by the Managing Member in connection with the acquisition and disposal of a Series Asset, (ii) conduct an annual review of the Company’s acquisition policy, (iii) provide guidance with respect to, material conflicts arising or that are reasonably likely to arise with the Managing Member, on the one hand, and the Company, a Series or the Economic Members, on the other hand, or the Company or a Series, on the one hand, and another Series, on the other hand, (iv) approve any material transaction between the Company or a Series and the Managing Member or any of its Affiliates, another Series or an Economic Member (other than the purchase of interests in such Series), (v) provide guidance with respect to the appropriate levels of annual fleet level insurance costs and maintenance costs specific to each individual Series Asset, and review fees, expenses, assets, revenues and availability of funds for distribution with respect to each Series on an annual basis and (vi) approve any service providers appointed by the Managing Member in respect of the Series Assets.

Time is Money Join Law Insider Premium to draft better contracts faster.